Erectile dysfunction (ED) is defined as the consistent inability to obtain or maintain an erection for satisfactory sexual relations. The past 20 years of basic science research on erection physiology has been devoted to investigating the pathogenesis of ED and has led to the conclusion that ED is predominately a disease of vascular origin with dramatic changes occurring in the endothelium. Research has also led to an understanding of the biochemical factors and intracellular mechanisms responsible for corporal smooth muscle contraction and relaxation and the influence of endothelium-derived relaxing factors. The development of methods to deliver both stem and endothelial cells to the penis has kindled a keen interest in treating ED with gene-and cell-based therapies. In this paper, erection physiology and stem cell biology is reviewed, and the potential application of novel cell-based therapies for the treatment of ED is discussed.
Introduction
Erectile dysfunction (ED) is defined as the pervasive inability to achieve or maintain an erection of sufficient quality for sexual intercourse. 1 Erections require the synchronized upsurge in penile artery inflow, dilation of corporal smooth muscle and occlusion of venous outflow. Any factor that compromises these structural changes may lead to ED. 2 Vascular disease is a major cause of ED, and several cardiovascular risk factors such as smoking, aging, hyperlipidemia, diabetes and hypertension are strongly correlated to ED. 3, 4 Injury to the cavernous nerves during pelvic surgeries (for example, radical prostatectomy, radical cystoprostatectomy) comprises an appreciable number of ED cases as well. 5 Other documented causes of ED are side effects of various medications, direct trauma to the genitals, endocrine disorders, and fibrosis of the penile vasculature and corporal smooth muscle. 6 To achieve penile tumescence, smooth muscle within the corporal sinusoids must relax and dilate. In the flaccid state, the contractile machinery of penile smooth muscle is tonically activated, thus decreasing luminal space and prohibiting engorgement. 7 Nitric oxide (NO) is now understood to be a key mediator in diminishing penile smooth muscle tone by increasing the production of cGMP. 8, 9 In turn, cGMP activates a cGMP-dependent protein kinase that phosphorylates and activates downstream promoters of vasodilation. 8, 9 Upon neurogenic stimulation, NO is released from nitrergic axons and acts to initiate an erection. 9 As engorgement begins, shear stress within the penile vasculature activates the production of endothelium-derived NO, a critical component in the maintenance of erection. 10 The etiological theme linking both vasculogenic and neurogenic ED is the loss of normal cellular function (for example, endothelial dysfunction) or death of the cells themselves (for example, neuronal and smooth muscle apoptosis following iatrogenic nerve trauma). Current pharmacological agents for vasculogenic ED like PDE5 inhibitors improve cGMP-dependent smooth muscle relaxation in the penis. This form of therapy, however, generally lacks efficacy in treating intractable ED patients such as men with advanced diabetes or postradical prostatectomy. 11, 12 Apoptosis of damaged neurons, Schwann cells and target tissues often results in the irreversible loss of function, creating a situation largely unresponsive to current oral medications. 13 Clearly, any therapeutic strategy for ED that aims at rejuvenating dysfunctional cells or replacing lost or critically damaged cells would be of immense value.
In concert with the growing interest in evaluating cell-based therapies for various human diseases, a few pioneering studies have recently appraised cellbased therapies in animal models of ED. [14] [15] [16] [17] While still at a germinal stage, this approach has so far yielded encouraging results for treating both vasculogenic and neurogenic ED. By rejuvenating or replacing defective penile tissues with stem cells, it is conceivable that cell-based therapies could result in permanent functional restoration. Such a potential outcome stands in stark contrast to current therapies that require continuous intervention. Stem cell-based therapy may also offer an option for those individuals with presentations of ED unresponsive to currently available medications (PDE5 nonresponders). The intent of this review is to construct a framework in which to interpret these pioneering studies and hopefully spur further research into stem cell-based therapies for ED. In addition, we will review our current understanding of endothelial progenitor cells (EPCs) in erectile biology.
The nature of stem cells
As the fundamental building blocks of life, all tissues are composed of cells. Owing to age, trauma, and genetic and degenerative diseases, cell death is all but unavoidable and leads to many of the maladies currently faced by clinicians, including Parkinson's disease (neurons), Fuchs' dystrophy (corneal endothelium), sarcopenia of aging (skeletal myocytes), heart failure (cardiomyocytes), diabetes mellitus (pancreatic b-cells) and compressive joint degeneration (chondrocytes). [18] [19] [20] [21] [22] [23] Because cell senescence and degeneration increases with time, older individuals are acutely prone to cell loss and consequent disease. 24 In this population in particular, pharmacological agents may be largely ineffectual at stimulating the inherent regenerative capacity of the failing tissue. It is evident that in many conditions an alternative to drug therapy is needed which focuses on the transplantation of healthy donor cells or restoration of tissue-resident stem cells, which may then repopulate and functionally improve compromised tissues.
Stem cells are by definition capable of (1) selfrenewal, (2) differentiation into one or more phenotypes and (3) functional reproduction of the damaged tissue. 25 The differentiation capacity of stem cells falls along a gradient of potency. Restricted to early development, totipotent cells are those with the capacity to differentiate into not only all the cells of an organism, but also the extraembryonic tissues. 26 Pluripotent stem cells are capable of giving rise to every cell phenotype of the adult, thus comprising all three embryonic layers: endoderm, mesoderm and ectoderm. 27 Embryonic stem cells (ESCs) are the most widely acknowledged example of pluripotent cells. Lineage-restricted potency (and loss of unlimited self-renewal) is a feature of multipotent, tissueresident stem cells such as hematopoietic stem cells residing in the bone marrow, which are capable of repopulating erythroid, myeloid and lymphoid cells. 28 With yet more limited differentiation potential, progenitor cells are loosely used in the literature to refer to cells capable of adopting a single mature phenotype. 29 While ESCs, as their name implies, are restricted temporally to the early zygote, human adults possess more restricted stem cells responsible for the regular replacement of dying cells. 24 Adult stem cells are believed to exist in low numbers in most, if not all, adult tissues. Some tissues and organs now known to inhabit tissue-resident stem cells are the liver, small intestine, stomach, skin, cornea, bladder, brain, lung, prostate, esophagus and heart, among several others. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Unlike ESCs, their lineage potential is likely restricted to their indigenous tissue. Many tissue-resident stem cells exist in a quiescent state but can reenter the cell cycle when stimulated. 41 Certain adult stem cells reside in particular reservoirs within the body and become mobilized to the blood stream upon demand, ultimately homing to the distressed tissue. 42 Intriguingly, some adult stem cells may in fact be pluripotent, such as the much-publicized multipotent adult progenitor cells within bone marrow. 43 
Cell-based therapies for erectile dysfunction
The application of cell-based therapies for ED is relatively new. 44 Nevertheless, the prospects of treating ED with healthy cells is very intriguing and may eventually offer a more curative intervention. While pharmacological agents like the PDE5 inhibitors (sildenafil, vardenafil and tadalafil) have clear benefits, their actions are necessarily ephemeral and treatment is relatively costly. Gene-based therapies, though effective in animal models of ED as a more lasting approach, carry substantial risks of random transgene expression and inflammatory effects. 45 Consequently, the most likely application for gene-based therapies may be the in vitro manipulation of cells prior to transplantation. Gene-and cell-based therapies may thus act synergistically. As described below, such a technique using endothelial nitric oxide synthase (eNOS)-transduced mesenchymal stem cells (MSCs) has already shown great efficacy in improving endothelial Cell-based therapy for erectile dysfunction TD Strong et al function by enhancing NO bioavailability and cGMP concentration in the penis. 16, 46, 47 With or without concurrent genetic modifications, cell-based approaches may offer significant benefits over both in vivo gene therapy and pharmacological agents (Table 1) .
Cell-based therapies can be used to replace dysfunctional or dying cells in a way that may obviate the need to comprehend the subtle pathological deviations in molecular pathways leading to ED. To a considerable extent, cell-based therapies are able to treat comprehensive molecular pathologies of damaged tissues. Consequently, understanding the precise nature of the dysfunction may not be critical. The new cells, being functional simulacra to the healthy native tissue, seemingly take over the proper function of the damaged cells. In the case of ED, these cells could functionally replace damaged endothelial cells, smooth muscle cells or neurons. Clearly, it is an oversimplification to discount the need to probe the molecular underpinnings of ED, but much of the promise of cell-based therapies lies in their well-documented abilities to either wholly replace damaged cells or secrete factors in a paracrine fashion that somehow repair dysfunctional cells, seemingly irrespective of the specific pathophysiology. Although stem cell-based approaches for treating ED are new, the few pioneering studies have reported very promising results, some documenting long-term functional improvement ( Table 2 ). Reviewed below are the known studies that have explored the potential for using stem or progenitor cells in the treatment of ED (Figure 1 ).
Vasculogenic erectile dysfunction
The natural aging process and diseases of the cardiovascular system such as diabetes, hypertension, hypercholesterolemia, dyslipidemia and atherosclerosis greatly increase the risk of vasculogenic ED. 4, 48, 49 In the above conditions, the systemic vasculature is commonly taxed by endothelial dysfunction, a complex condition that may not be fully reversible through treatment with pharmacological agents. In patients with hypertension and atherosclerosis, endothelial dysfunction of the penile vasculature is often the primary cause of ED. 50, 51 If the penile endothelial cells are compromised, then replacing these cells with stem or progenitor cells may be a viable therapeutic option. Two stem/progenitor cell populations, MSCs and Mesenchymal stem cells. Mesenchymal stem cells are intermixed within the bone marrow stroma in a sparse population of multipotent stem cells with the unique capacity to differentiate into mesodermal tissues such as osteoblasts, chondrocytes and adipocytes. 52 MSCs have the additional ability of differentiating into non-mesodermal phenotypes such as neurons, lung epithelial cells and hepatocytes. [53] [54] [55] More recently, MSCs have been isolated in a number of other tissues and organs including placenta, cord blood and adipose tissue, as well as several other adult tissues. [56] [57] [58] [59] [60] [61] [62] [63] [64] The presence of MSCs in a number of different organ systems has lead some to contend that these cells may exist within virtually every postnatal organ. 64 The combined attributes of multipotency, robust proliferation ex vivo and amenability to genetic manipulation have inspired many researchers to study the potential clinical applications of MSCs. In animal experiments, MSCs have shown the capacity to home to damaged tissues and may differentiate into the necessary mature phenotypes. 65, 66 Clinical applications are being presently undertaken or imminent for several common maladies such as heart disease, neurological diseases (for example, amyotrophic lateral sclerosis) and lysosomal storage diseases (for example, Hurler syndrome). 67 The method by which MSCs improve the regeneration of various tissues has been ascribed to direct differentiation, fusion into heterokaryons with resident cells and the release of paracrine growth factors. [68] [69] [70] The ability for MSCs to home to sites of tissue stress has also suggested the possibility of using these cells as targeting vehicles for gene therapy.
71 Surprisingly, likely in part owing to their frequent lack of human leukocyte antigens class II, allogeneic MSCs can often escape the notice of the immune system. 72 Haploidentical or host MSCs co-transplanted with allogeneic grafts have demonstrated an immunomodulatory effect preventing graft-versus-host disease in animal models. 73, 74 The documented multipotency, high engraftment and immune suppression of MSCs make them an intriguing source for cell-based therapy for ED. Given the right environment, MSCs have the established capacity to differentiate into diverse cell types and thus conceivably may be able to replace damaged or dysfunctional tissues of the penis. MSCs can express endothelial and smooth muscle phenotypes in vitro and have been used successfully to repair vascular diseases and insults in vivo, suggesting the possibility that this stem cell population may be effective in replacing or rejuvenating the dysfunctional analogous tissues within the penis. [75] [76] [77] [78] Currently, little is known about the effect of MSCbased therapy on erectile physiology. However, two recent investigations have documented the utility of injecting MSCs into the penile corpora cavernosa. 16, 17 Bivalacqua et al. 16 assessed the potential for MSCs alone or transduced with eNOS to differentiate into new endothelial and smooth muscle cells, as well as their effect on endothelium-derived NO bioavailability and erectile physiology (Figure 1) . To obtain MSCs, bone marrow was collected from young male rats. Rat MSCs (rMSCs) were isolated, ex vivo expanded for 0-3 passages and transduced with eNOS. The current and previous studies by this group have documented that rMSCs can be readily transduced with an adenovirus expressing bovine eNOS and consequently express long-term high levels of eNOS protein, eNOS activity and cGMP concentrations. 16, 46 Aged rats, known to have diminished NO bioavailability and resultant vasculogenic ED, were injected intracavernously with vehicle, rMSCs alone (with or without transduced lacZ), or rMSCs transduced with eNOS. After 7 and 21 days, engraftment, differentiation, eNOS expression/activity and erectile responses were assessed.
This initial study showed that at 7 days following injection of lacZ-transduced rMSCs, rMSCs had adhered to a number of cell types in the penis, including the vascular endothelium and smooth In the ensuing paper, Song et al. 17 assessed the potential of immortalized human MSCs (hMSCs) to differentiate into endothelial and smooth muscle cells within the corpora cavernosa of rats. hMSCs were isolated from fetal spinal vertebrae and immortalized through the introduction of the v-myc oncogene. The immortalized hMSCs were injected into the corpora cavernosa of young rats (10 weeks), and the corpora cavernosa were collected after 2 weeks. Prior to injection, cultured hMSCs did not express the endothelial markers CD31 and vWF or the smooth muscle markers desmin, calponin or smooth muscle actin. Two weeks after injection, however, immunofluorescence revealed that many of the injected hMSCs began expressing the endothelial markers CD31 and vWF, as well as smooth muscle markers, namely calponin. This study emphasized the differentiation capacity of hMSCs in young, healthy rats; physiological measurements of erectile function were not collected. It is important to note that although the MSCs in this study demonstrated a capacity to adopt smooth muscle and endothelial selective markers, immortalizing donor cells is impracticable as a potential therapeutic strategy as it introduces an oncogenic risk. In addition, it would have been instructive to observe whether these MSCs could ameliorate the erectile responses within a model of ED.
In combination, these early studies suggest that allogeneic MSCs have the capacity to differentiate into endothelial and smooth muscle cells after being injected into the corpora cavernosa of rats. MSCderived endothelial cells within the corpora cavernosa also appear to be fully functional through the increase in physiological response and relevant molecular markers in an animal model of vasculogenic-related ED. 16 Additionally, the lack of immune response suggests the apparent safety of allogeneic MSC cell-based therapy for ED. 16 Further studies are clearly warranted and ongoing.
Endothelial progenitor cells. One of the most exciting discoveries in vascular biology came in 1997 with the apparent detection of EPCs circulating within human blood. In their seminal paper, Asahara et al. 79 showed that under specific culturing conditions peripheral blood mononuclear cells (PBMCs) enriched for CD34 þ could ostensibly differentiate into endothelial-like cells. Consistent with mature endothelial cells, these cells expressed the endothelial markers CD31, CD34, VEGFR2, Tie-2 and eNOS, as well as binding Ulex lectin, accumulating acetylated low-density lipoprotein, and forming vessel-like structures in Matrigel. 79 Supported by a subsequent flurry of publications, this study suggested the existence of a population of circulating, bone marrow-derived cells that can differentiate into mature endothelial cells under particular stimuli. The discovery of endothelial progenitors circulating in the peripheral blood has potentially monumental implications for angiogenic therapy.
The characterization of EPCs is the subject of current debate. For much of the past decade, the vast majority of studies have used flow cytometry to isolate EPCs according to a suite of surface antigens, most frequently CD34, VEGFR2 and AC133. [80] [81] [82] [83] [84] [85] [86] Other researchers have cogently argued that emphasizing surface antigens overlooks normal modulations in antigen expression and ignores cell behavior, suggesting instead that EPCs may be better defined by their growth dynamics in vitro. 87 Cell colonies derived from PBMCs grown in culture are generally classified as either early or late outgrowth. 82, 88 Early outgrowth colonies arise from the nonadherent subset of PBMCs within a few days while late outgrowth colonies arise from the adherent subset of PBMCs between 1 and 3 weeks. 89 While early outgrowth colonies typically possess surface antigens common to hematopoietic cells, late outgrowth colonies appear to possess antigens restricted to endothelial cells. 90 Combined with the observation that late outgrowth cells are both clonogenic and robustly prolific (characteristics of true stem cells and atypical in early outgrowth colonies), some have suggested that this cell population represents the most viable source of endothelium for adult angiogenesis and vasculogenesis. 89, 91 Others, however, have suggested the more ecumenical view that perhaps any endothelial precursor, regardless of its origin, antigens and Cell-based therapy for erectile dysfunction TD Strong et al growth dynamics, that can functionally insinuate itself within the endothelium should be considered an EPC. 87 According to this perspective, it is possible that different progenitor reservoirs are used to create endothelial cells under specific circumstances.
By methods that are still becoming elucidated, bone-marrow-derived EPCs are stimulated by various cytokines to emigrate from the bone marrow to sites of tissue stress such as hypoxia. 92 Within the hypoxic vasculature, EPCs bind to the endothelium in an antigen-dependent manner, chiefly through the CXCR4/SDF-1 axis, and either secrete angiogenic factors, incorporate themselves within the endothelium or perhaps extravasate into the extracellular matrix and form new blood vessels de novo. 93 EPCs of various origins and phenotypes have been used with some very promising results in studies on laboratory animals. [94] [95] [96] [97] [98] [99] Indeed, the announcement of EPCs circulating within the blood spurred a very rapid, and greatly premature to some, advancement to clinical trials. 100 Conceivably, endothelial progenitors could be used to hasten neoangiogenesis following ischemic events caused by trauma or cardiovascular disease. A litany of clinical trials has provided evidence that either unfiltered PBMCs or PBMCs enriched for EPC characteristics can in some cases increase neoangiogenesis and positively affect clinical outcome. 101 Much of the current research has emphasized heart failure following cardiac infarct, though the variety of potential applications is profound.
Innumerable studies have shown strong epidemiological associations between ED and cardiovascular disease, and others have linked ED as an independent risk factor for major cardiovascular events. 4, 102, 103 Linking ED and cardiovascular disease appears to be the pathological phenomenon of endothelial dysfunction, a condition characterized by reduced NO bioavailability and a concomitant increase in vascular tone, as well as other phenotypic changes to the corporal smooth muscle. 104 Endothelial dysfunction is believed to be a clinically silent harbinger of impending cardiovascular disease and is notably present in at-risk patients, such as those with hypertension, diabetes and dyslipidemia. 104 Increased oxidative stress is largely considered to be a major factor leading to endothelial dysfunction. 105 Because both the incidence of ED and lowcirculating EPCs are independently correlated to an increased risk of cardiovascular disease, several recent efforts have been made to measure the association between ED and circulating EPC levels. One of the intentions of these studies is to determine whether circulating EPC levels can accurately predict ED and thus serve as a readily available diagnostic biomarker for incipient endothelial dysfunction (Figure 1 ). In the first study of its kind, Foresta et al. 106 found significantly lower levels of circulating CD34 þ /AC133 þ EPCs within individuals having ED, though not necessarily having known cardiovascular risk factors. In another study, Baumhäkel et al.
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showed that circulating AC133 þ EPCs, though not CD34 þ /VEGFR2 þ EPCs, were diminished in patients with both ED and high risk for cardiovascular disease, and decreased EPCs served as an independent predictor of ED.
If circulating EPCs are indeed diminished in individuals with ED the reason may lie in the requirement of eNOS to regulate the stem cell microenvironment within the bone marrow. Expression of the protease matrix metalloproteinase (MMP)-9 in the bone marrow stroma is dependent on eNOS activity. 108 By cleaving membrane-bound Kit ligand (mKitL) to soluble Kit ligand (sKitL), MMP-9 may be instrumental in the release of various stem cell populations from the bone marrow, including EPCs. 109 Recently, PDE5 expression has been documented in the bone marrow. 110 Because PDE5 inhibitors prolong NO signaling, some studies have looked at the ability of various PDE5 inhibitors to mobilize EPCs, possibly through increased levels of MMP-9. In a small study of healthy individuals, oral PDE5 inhibitor therapy was shown to significantly increase EPC numbers after only 4 h. Adding to the well-known acute function of PDE5 in increasing NO bioavailability, this study suggests that PDE5 inhibitor therapy may exert a long-term function through stimulating eNOS signaling within the bone marrow stroma and enhancing EPC mobilization. 106 In a further study, which included ED patients with or without known cardiovascular risk factors, Foresta et al.
111 noted a significant increase in both CD34 þ /AC133 þ EPCs and brachial artery flowmediated dilation (a clinical measure of endothelial function) after 3 months treatment with the PDE5 inhibitor, Tadalafil. The results of this study may be interpreted to suggest a possible link between the restoration of circulating EPCs and improved endothelial function. In a subsequent study, patients with ED and varying intima media thicknesses of the carotid artery were given the oral PDE5 inhibitor vardenafil in a single 20 mg dose. 110 Circulating EPC numbers increased in all test and control groups 4 h after PDE5 inhibitor treatment, though individuals with higher grades of carotid intima media thickness had significantly lower increases in EPCs than the control group. The authors interpreted these results as individuals with more significant cardiovascular risk factors and endothelial dysfunction may deficiently mobilize EPCs under PDE5 inhibitor stimulus, and thus diminished EPC mobilization may be a surrogate test for a patient's capacity for endothelial regeneration and response to PDE5 inhibitor therapy for the treatment of vasculogenic ED.
Despite the recent flurry of studies demonstrating a reduced number of EPCs in individuals with ED, Cell-based therapy for erectile dysfunction TD Strong et al currently it is unclear if circulating EPCs will serve as an independent biomarker of ED. Diminished levels of circulating EPCs are associated with several known clinical conditions, which may or may not be linked with concurrent ED. One may conclude that low EPCs can be strongly correlated with global endothelial dysfunction of the peripheral vasculature. Recent evidence evaluating circulating EPCs in ED patients may correlate well with penile vascular dysfunction in a select group of patients; however, definitive conclusion that low EPCs are specifically diagnostic or predictive of imminent ED is unclear at this time and warrants further investigation. Rather than diagnosing or foretelling ED, the greatest benefit of EPCs may be in their direct therapeutic potential. If, indeed, EPCs turn out to be a natural reservoir of incipient endothelial cells, then cellbased therapies aimed at delivering EPCs to the dysfunctional corpora cavernosa may potentially yield significant improvements in erectile response.
Neurogenic erectile dysfunction
For neurogenic ED caused by iatrogenic intervention, trauma or neurological disease, cell-based therapies may offer a novel way of regenerating neural signaling. A common sequela to radical prostatectomy for the treatment of prostate cancer is significant nerve damage and death owing to the unfortunate proximity of the cavernous nerves to the prostate.
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Chronically axotomized peripheral nerves frequently result in poor regeneration, possibly caused by apoptosis of the involved neurons, Schwann cells, and smooth muscle and endothelial cells. 112 Oral pharmacotherapy is unlikely to effectively resurrect all these tissues. For such scenarios, cell-based therapy may be the most promising approach.
Embryonic stem cells. Embryonic stem cells are pluripotent cells derived from the inner cell mass of blastocysts or from single blastomeres. 113, 114 In the lab, ESCs have been coaxed to differentiate into a vast number of mature cells originating from all three embryonic germ layers including cardiomyocytes, hepatocytes, endothelial cells, keratinocytes, insulin-secreting cells, neurons, osteoblasts, chondrocytes and retinal cells, to name just a few. [115] [116] [117] [118] [119] [120] [121] [122] ESC therapy has lagged, however, partly owing to immunogenicity and the teratogenic risks of transplanting pluripotent stem cells. 123 Perhaps signifying their great potential, ESCs were the first stem or progenitor cells to be evaluated for treating ED (Figure 1 ). 14 In this study, the authors isolated ESCs from rat blastocysts and directed them to differentiate into neural embryonic stem cells (NESCs) by introducing brain-derived neurotrophic factor linked to enhanced green fluorescent protein. Rats were initially divided into four surgical groups, those undergoing (1) sham surgery, (2) bilateral cavernous nerve crush plus intracavernous vehicle injection, (3) bilateral cavernous nerve crush plus NESC injection into the major pelvic ganglion (MPG) and (4) bilateral cavernous nerve crush plus injection of NESCs into the crus of the corpora cavernosa. Electrical stimulation of the cavernous nerve was performed to determine erectile responses 3 months following NESC injection. In addition, penis and MPGs were collected and analyzed for neurofilament and nicotinamide adenine dinucleotide phosphate (NADPH) diaphorase expression.
After the 3-month interval, erection physiology measurements demonstrated a significant decline in erectile response in each of the bilateral nerve crush groups compared to the sham group. However, the groups receiving an NESC injection in either the crura or MPG exhibited significantly improved erectile responses compared to the group receiving vehicle. Upon immunohistochemical staining, the two groups receiving NESCs showed significantly higher neurofilament expression compared to vehicle in both the MPG and dorsal cavernous nerve. In the distal cavernous nerve, the group receiving crural NESC injection revealed higher expression of neurofilament than the vehicle group. Impressively, crural injection of NESCs yielded no difference between neurofilament expression in the experimental and sham groups in both the MPG and dorsal cavernous nerve. Similarly, MPG injections of NESCs suggested no difference of neurofilament expression between experimental and sham groups in the dorsal cavernous nerve. Measurements of NADPH-diaphorase showed no difference between the groups receiving NESCs and vehicle, though the authors noted some qualitative improvements in neuronal morphology within the NESCtreated groups.
This study revealed that ESCs directed along a neural lineage are able to exert some neuroprotective effects. Whether the NESCs differentiated into new neurons, glia or transiently secreted neurotrophic factors is unknown. The authors could not identify transplanted cells within the cavernosa suggesting that perhaps these cells acted in a paracrine manner for a limited amount of time. Other possibility offered by the authors is that these stem cells served as scaffolding for regenerating axons or differentiated into mature cells that eventually stopped expressing the transfected genes, thus no longer being detectable. Additional studies are clearly necessary to determine the mechanisms involved in neuronal regeneration or protection after ESCbased therapy in models of cavernous nerve injury.
Muscle-derived stem cells. When skeletal muscle is enzymatically degraded into its constituent cells and serially plated in such a manner to obtain Cell-based therapy for erectile dysfunction TD Strong et al low-adherence cells, a heterogeneous population of myogenic progenitors of uncertain ontogenetic derivation can be isolated. [124] [125] [126] These cells proliferate robustly, maintain long-term self-renewal capability and express myogenic and stem cell antigens. 125 These early myogenic precursors, termed muscle-derived stem cells (MDSCs), are capable of adopting phenotypes of vastly diverse cell types, including mesodermal tissues like skeletal muscle, endothelium and hematopoietic cells, as well as cells of ectodermal derivation like Schwann cells. [126] [127] [128] [129] In urological tissues, MDSCs have been transplanted with surprising efficacy into the smooth muscle of damaged bladder and urethra, resulting in functional recovery of muscle control and diminished incontinence. 130, 131 Remarkably, innervation of these tissues improved, suggesting either direct differentiation into neural cells and/or the secretion of neurotrophic factors. 130 The well-documented robust engraftment of MDSCs may be attributable to improved neoangiogenesis resulting from direct differentiation or secretion of angiogenic factors.
In the only study to consider MDSCs for the treatment of ED, Kim et al. 15 isolated MDSCs from skeletal muscle of female rats and serially plated them to remove contaminating cells (Figure 1 ). The enriched MDSCs were then transduced with lacZ and injected into both corpora cavernosa immediately prior to bilateral cavernous nerve injury in a rat model. Rats undergoing sham surgery (bilateral cavernous nerve transection plus intracavernous Hank's balanced salt solution injection) demonstrated markedly lower maximal intracavernous pressure (ICP) under electrical stimulation, as well as decreased cavernous expression of the panneuronal marker protein gene product (PGP) 9.5, at 2 and 4 weeks after surgery. Experimental groups receiving bilateral injections of 1 Â 10 6 MDSCs (each corporal body) had demonstrably greater maximal ICPs and cavernous PGP 9.5 expression compared to sham surgery at both 2 and 4 weeks following surgery. MDSC-treated groups showed comparable levels of cavernous PGP 9.5 to the control group, but maximal ICP was clearly lower than the control group. Further histology revealed the presence of lacZcontaining cells integrated within the smooth muscle cells.
The significance of this study is the apparent identification of a readily accessible cell population for cell-based ED therapy. Clearly, this is an intriguing study deserving further exploration. Owing to their multipotency, not to mention their robust proliferation and high engraftment, MDSCs may prove to be a preferred source for cell-based ED treatment. In this study, MDSCs assisted in the regeneration of nerves, as was evidenced by erectile response and neuronal cell concentration in the corpus cavernosum. The authors concede that it is uncertain exactly how the MDSCs exert their neuroprotective effects, but they offer the possibility of direct differentiation into cells with neuronal phenotypes. Such a finding would be very interesting as MDSCs are primarily used in basic and clinical research for their muscle-regenerating capacity rather than their ability to protect or differentiate into neuronal cells. Even though allogeneic donor cells were used in this study, it is likely that autologous cells could be used as well, thus eliminating the omnipresent issue of immune rejection. There is some evidence, however, that allogeneic MDSCs tend not to elicit a strong immune response. 132 The future of stem cell-based therapies for erectile dysfunction
Because endothelial dysfunction leads to the abrogation of cardiovascular responses to vasodilatory stimuli, repairing or replacing dysfunctional endothelium could potentially be an effective therapy. Currently, EPCs have been evaluated primarily as biomarkers and for their potential to treat acute ischemic events. Because EPCs are likely the main reservoir of future endothelial cells and could hypothetically be used to replace impaired endothelium, it would be reasonable to evaluate EPCs for treating various forms of endothelial dysfunction such as ED. Whether EPCs are resistant to the environmental and endogenous insults that result in ED is unknown and must be thoroughly determined. If autologous EPCs are also compromised, allogeneic transplants may be a viable option.
In the penis, further studies are needed to probe whether EPCs are able to efficiently insinuate themselves within the endothelium of the corpus cavernosum and alter NO bioavailability. At least one research group believes that EPCs are native inhabitants of certain blood vessel walls, and it would be instructive to determine whether EPCs are embedded within the penile vasculature and can be stimulated to repair dysfunctional penile endothelial cells. 133 Motivated by the premise that endothelial dysfunction is fundamental in the development of ED, our lab is currently evaluating EPC transplantation and mobilization for treating vasculogenic ED. It may also be possible to stimulate the migration and homing of native EPCs with pharmacological agents. G-CSF and AMD3100 are potent stimulators of EPC migration and may serve to increase peripheral EPC levels in individuals with ED. 134 In addition, in situ modulation of penile endothelial antigens (for example, increasing expression of EPC-specific binding ligands) may enhance the homing of circulating EPCs to the intended penile vasculature.
Neurogenic-mediated erectile failure secondary to injury of the neurovascular bundle during radical Cell-based therapy for erectile dysfunction TD Strong et al prostatectomy is a common sequela of men undergoing this operation. Currently, intense research is devoted to establishing novel neuroprotective agents. However, with the recent evidence utilizing stem cells to either regenerate or protect injured nerves in animal models of postradical prostatectomy, ED stem cell therapy may offer distinct advantages over current drug regimens. Because the corporal bodies are primarily composed of smooth muscle cells that become fibrotic and less compliant with various forms of ED, it may prove highly beneficial to replace damaged smooth muscle with myogenic stem cells. A number of readily available stem cell populations, such as MSCs and MDSCs, are capable of differentiating into smooth muscle cells. Hypothetically, transducing stem cells expanded ex vivo with collagenase or similar proteolytic enzymes prior to intracavernous delivery may help to degrade the pathological deposition of collagen within the smooth muscle matrix.
The potential therapies considered so far involve the transplantation of exogenous cells, but it may be that various stem cell populations already exist naturally within the penile parenchyma. If they are indeed present, it may prove advantageous to modulate their activity with pharmacological agents. Stimulating these intrinsic stem cells to proliferate and functionally replace damaged or dysfunctional tissues may improve some forms of ED. On the other hand, unregulated stem cell proliferation in pathological conditions may need to be diminished. Recently, cultured tunica albuginea cells have demonstrated multipotency and expression of a putative stem cell marker, possibly hinting at the presence of native stem cells within at least one penile tissue. 135 The aberrant proliferation of fibroblasts in Peyronie's disease (PD) may be the result of stem cell activation; inhibiting these stem cells with pharmacological agents may offer a unique approach to treating PD.
There are potential drawbacks to stem cell-based therapies for ED. As a general caveat, stem cell treatments hold the risk of unintended differentiation, along with the ensuing complications. If the differentiation pathway is not thoroughly controlled, stem cells injected into the penis may very well differentiate into ectopic fibroblasts or osteoblasts, thus potentially creating a significantly worse situation. 135 As a result, it is critical for the researcher to evaluate such rogue differentiation by determining the presence of unintended phenotypes. In addition, inflammation and graft rejection with allogeneic cells may be a formidable hurdle to overcome, though perhaps no greater an obstacle than that confronted by the various allogeneic cell-and tissue-based transplants currently being successfully conducted.
Research into stem and progenitor cell therapy for ED is currently at an early stage, and studies considering the long-term effects of stem cell therapy for ED are lacking. Nevertheless, the therapeutic success of the pioneering studies suggests this approach may offer an effective and long-lasting treatment option. The observation that distinct stem cell populations have exhibited milieu-dependent differentiation and functional recovery in models of ED implies that a variety of cell-based approaches may prove efficacious for both vasculogenic-and neurogenic-mediated penile vascular dysfunction. Prospective researchers should be encouraged and motivated by these early studies to refine methodologies and investigate yet further stem cell populations, with or without gene therapy, for superior efficacy. If earnestly and thoroughly pursued, stem and progenitor cell therapy could become a lasting and possible curative treatment regimen for ED.
